This inventor holds 5 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: Allgenesis Biotherapeutics Inc., Ap Biosciences Inc.. Active years: 2021-2025.
Company Filing History:
5 out of 9 
1 out of 8 Years Active: 2021-2025
Title: Pei-Tzu Wu: Innovator in Biologics and Angiogenesis Inhibition
Introduction
Pei-Tzu Wu is a prominent inventor based in Taipei, Taiwan. She has made significant contributions to the field of biologics, particularly in the area of angiogenesis inhibition. With a total of 5 patents to her name, her work has the potential to impact therapeutic approaches in various medical conditions.
Latest Patents
Pei-Tzu Wu's latest patents include innovative developments in VEGFR fusion protein pharmaceutical compositions. These inventions relate to biologics that inhibit angiogenesis, specifically through fusion proteins that target both the integrin activated pathway and another angiogenic factor-activated pathway. The formulations and methods for producing and utilizing these fusion proteins are crucial advancements in the field.
Career Highlights
Throughout her career, Pei-Tzu Wu has worked with notable companies such as Allgenesis Biotherapeutics Inc. and Ap Biosciences Inc. Her expertise in biologics has positioned her as a key player in the development of new therapeutic solutions.
Collaborations
Pei-Tzu Wu has collaborated with talented individuals in her field, including Tan Nguyen and Kevin Zen. These partnerships have fostered innovation and contributed to her successful patent portfolio.
Conclusion
Pei-Tzu Wu's contributions to the field of biologics and angiogenesis inhibition highlight her role as an influential inventor. Her work continues to pave the way for advancements in medical therapies.